2023

Emergent BioSolutions has sold its travel health business to Bavarian Nordic

Client: Emergent BioSolutions

Client Location: United States

Target: Travel health business of Emergent BioSolutions

Target Location: United States

Acquirer: Bavarian Nordic

Acquirer Location: Denmark

Client Description: Emergent BioSolutions (“Emergent”) provides solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that are developed and manufactured for governments and consumers. Emergent also offers a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers worldwide.

Acquirer Description:  Bavarian Nordic is a fully integrated vaccines company focused on the research and development, manufacturing and commercialization of life-saving vaccines. Bavarian Nordic is a global leader in smallpox and mpox vaccines, which have been developed through its long-standing partnership with the U.S. Government to enhance the public health preparedness through a strong portfolio of vaccines for travelers and endemic diseases.

Connect with a Senior Team Member

Meet our Senior Team

Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.